BICARA THERAPEUTICS INC. - COMMON STOCK

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

27 1 2025 08:00:15 提供 Nasdaq GlobeNewswire

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12 11 2024 07:30:49 提供 Nasdaq GlobeNewswire

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

11 11 2024 16:01:02 提供 Nasdaq GlobeNewswire

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 9 2024 16:01:00 提供 Nasdaq GlobeNewswire